De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

Ma Ai Thanda Han; Raquel Olivo; Catherine J Choi; Nikolaos Pyrsopoulos

doi:10.4254/wjh.v13.i12.1991

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

World J Hepatol. 2021 Dec 27;13(12):1991-2004. doi: 10.4254/wjh.v13.i12.1991.

Authors

Ma Ai Thanda Han¹, Raquel Olivo², Catherine J Choi³, Nikolaos Pyrsopoulos⁴

Affiliations

¹ Department of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States.
² Department of Gastroenterology and Hepatology, Rutgers University, New Jersey Medical School, Newark, NJ 07103, United States.
³ Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07101, United States.
⁴ Department of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States.pyrsopni@njms.rutgers.edu.

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new acronym adopted from the consensus of international experts. Given the increasing prevalence of MAFLD in pre-transplant settings, de novo and recurrent graft steatosis/MAFLD are common in post-transplant settings. The impact of graft steatosis on long-term outcomes is unclear. The current knowledge of incidence rate, risk factors, diagnosis, long-term outcomes, and management of graft steatosis (both de novo and recurrent) is discussed in this review.

Keywords: De novo; Fibrosis; Graft steatosis; Metabolic dysfunction-associated fatty liver disease; Metabolic dysfunction-associated steatohepatitis; Recurrent; Survival.

Publication types

Review